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Introduction: Uveitis, a leading cause of preventable blindness around the world, is a critically 
underserved disease in regard to the medications approved for use. Multiple immunomodula-
tory therapy (IMT) drugs are appropriate for uveitis therapy but are still off-label. These IMT 
agents, including antimetabolites, calcineurin inhibitors, alkylating agents, and biologic agents, 
have been designated as “orphan drugs” and are widely used for systemic autoimmune diseases 
or organ transplantation.
Area covered: The purpose of this paper is to comprehensively review and summarize the 
approved orphan drugs and biologics that are being used to treat systemic diseases and to discuss 
drugs that have not yet received approval as an “orphan drug for treating uveitis” by the US 
Food and Drug Administration (FDA).
Our perspective: IMT, as a steroid-sparing agent for uveitis patients, has shown promising 
clinical results. Refractory and recurrent uveitis requires combination IMT agents. IMT is 
continued for a period of 2 years while the patient is in remission before considering tapering 
medication. Our current goals include developing further assessments regarding the efficacy, 
optimal dose, and safety in efforts to achieve FDA approval for “on-label” use of current IMT 
agents and biologics more quickly and to facilitate insurance coverage and expand access to 
the products for this orphan disease.
Keywords: immunomodulatory, orphan drug, steroid sparing, uveitis
Introduction
Uveitis is a major cause of severe visual impairment. It can occur either alone or as 
part of a systemic syndrome (systemic disease-associated autoimmune uveitis), such 
as one of the spondyloarthritides (including those complicating inflammatory bowel 
disorders and juvenile idiopathic arthritis [JIA]), Adamantiades–Behcet’s disease 
(ABD), Vogt–Koyanagi–Harada (VKH) syndrome, systemic lupus erythematosus, 
sarcoidosis, autoimmune hepatitis, and multiple sclerosis, in which the eye is one 
of several organs involved.1 Autoimmune-mediated uveitis treatment is divided into 
acute phase and maintenance therapy. The acute stage can be controlled with corti-
costeroid therapy.
The Standardization of Uveitis Nomenclature Working Group Guidelines recom-
mend the use of corticosteroids as first-line therapy for patients with active uveitis.2 
However, long-term corticosteroid treatment can cause serious systemic and ocular side 
effects, such as hypertension, diabetes, cataract, and glaucoma. Alternatively, immuno-
modulatory therapy (IMT) drugs are given as steroid-sparing agents and have shown 
good clinical results for both systemic diseases and ocular inflammatory diseases.3,4 
Given the side effects of chronic corticosteroid therapy and better understanding of 
the mechanisms of autoimmune-mediated uveitis, the aim of the treatment for patients 
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with noninfectious uveitis is steroid-free remission with IMT. 
A stepladder approach is a common practice in immune-
mediated uveitis: nonsteroidal anti-inflammatory drugs and 
conventional immunomudulatory agents are usually used 
before proceeding with biologic response modifiers.
IMT agents include the antimetabolites methotrexate, 
azathioprine, and mycophenolate mofetil; the calcineurin 
inhibitors that include cyclosporine, tacrolimus, and 
sirolimus; alkylating agents that include cyclophosphamide 
and chlorambucil; biologic response modifiers that include 
the tumor necrosis factor (TNF)-α inhibitors infliximab, adal-
imumab, etanercept, golimumab, and certolizumab; lympho-
cyte inhibitors that include daclizumab, rituximab, abatacept, 
and basiliximab; specific receptor antagonists that include 
anakinra, canakinumab, gevokizumab, tocilizumab, alem-
tuzumab, efalizumab, secukinumab, and ustekinumab; and 
interferon (INF) treatments. Refractory and recurrent uveitis 
requires immunomodulatory monotherapy or a combination 
protocol to control the inflammation. Continuing evidence 
shows that second-line agents, including antimetabolites, 
T-cell inhibitors, and alkylating agents, and biologics are 
effective in many patients, allowing reduction in steroid dose 
and preservation of visual function. Aggressive treatment 
may result in fewer complications and less recurrence.
Our team has reviewed IMT drugs approved by the US 
Food and Drug Administration (FDA) for use in uveitis.5 
In this study, we review and summarize conventional IMT 
drugs or biologics that have not received approval as an 
“orphan drug” from the FDA for use in noninfectious uveitic 
patients, despite having been approved for use in treating 
other systemic diseases or organ transplantation.
Orphan drug status in ocular 
inflammatory diseases
The Orphan Drug Designation program provides orphan 
status to drugs and biologics that are defined as those 
intended for the safe and effective treatment, diagnosis, or 
prevention of rare diseases/disorders that affect fewer than 
200,000 people in the USA, or that affect .200,000 persons 
but are not expected to recover the costs of developing and 
marketing a treatment drug.6
Although not approved as orphan agents for uveitis, there 
are many randomized clinical trials evaluating various IMT 
drugs and biologics used for ocular inflammatory diseases. 
These treatments have been approved as orphan drugs by 
the FDA to be used in malignancies, autoimmune disorders, 
and/or organ transplantation (Table 1). Table 2 shows the use 
and dosage of these drugs for the treatment of uveitis.
Table 1 Orphan drugs approved by the US Food and Drug Administration for use in systemic disease/organ transplantation that have 
not received orphan drug approval for use in uveitis
Generic  
names
Approved labeled indication
Methotrexate High-dose methotrexate for use with leucovorin rescue in patients with nonmetastatic osteosarcoma who have undergone 
surgical resection or amputation for the primary tumor
Tacrolimus Prophylaxis of organ rejection in kidney transplant patients converted from tacrolimus immediate release formulations in 
combination with other immunosuppressants; prophylaxis of organ rejection in patients receiving allogenic heart transplants
Infliximab For reducing signs and symptoms, and inducing and maintaining clinical remission in pediatric patients with moderately to 
severely active Crohn’s disease who have had an inadequate response to conventional therapy; for reducing signs and symptoms, 
and inducing and maintaining clinical remission in pediatric patients aged $6 years with moderately to severely active ulcerative 
colitis who have had an inadequate response to conventional therapy; treatment of moderately to severely active Crohn’s 
disease for the reduction of the signs and symptoms in patients who have an inadequate response to conventional therapies; and 
treatment of patients with fistulizing Crohn’s disease for the reduction in the number of draining enterocutaneous fistula(s)
interferon Treatment of chronic myelogenous leukemia (interferon α-2a); treatment of selected patients with AiDS-related Kaposi’s 
sarcoma (interferon α-2b [recombinant]); treatment of relapsing forms of multiple sclerosis to slow the accumulation of physical 
disability and decrease the frequency of clinical exacerbations (interferon β-1a); in ambulatory patients with relapsing–remitting 
multiple sclerosis to reduce the frequency of clinical exacerbations (interferon β-1b); delaying time to disease progression in 
patients with severe, malignant osteopetrosis (interferon γ-1b); adjuvant treatment of melanoma with microscopic or gross 
nodal involvement within 84 days of definitive surgical resection including complete lymphadenectomy (peginterferon α-2b)
Rituximab Treatment of patients previously untreated for CD20-positive chronic lymphocytic leukemia in combination with fludarbine and 
cyclophosphamide; for the use of Rituxan® (rituximab) in combination with glucocorticoids for the treatment of patients with 
wegener’s granulomatosis and microscopic polyangiitis 
Tocilizumab Treatment of active polyarticular juvenile idiopathic arthritis in patients aged 2 through 16 years
Anakinra Treatment of neonatal-onset multisystem inflammatory disease
Canakinumab Treatment of cryopyrin-associated periodic syndromes, in adults and children aged $4 years; treatment of active systemic 
juvenile idiopathic arthritis in patients aged 2 through 16 years
Alemtuzumab The treatment of patients with B-cell chronic lymphocytic leukemia who have been treated with alkylating agents and who have 
failed fludarabine therapy
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Methotrexate
As an antimetabolite and antifolate drug, methotrexate 
(formerly known as amethopterin) is a folic acid analog 
that irreversibly, competitively binds and inactivates the 
enzyme dihydrofolate reductase. Methotrexate also partially, 
reversibly, competitively inhibits thymidylate synthetase. 
Ultimately, DNA synthesis, DNA repair, RNA synthesis, 
and cell division (S-phase cell cycle specific) are inhibited.7 
Methotrexate suppresses both B and T cells. At low doses, 
it has little effect on cell-mediated immunity, but has been 
shown to depress acute-phase reactants. Therefore, it is 
suspected that the action of methotrexate is more likely 
anti-inflammatory than immunosuppressive.8,9 Potential side 
effects of methotrexate include nausea, diarrhea, fatigue, 
minimal hair loss, mouth ulcers, hepatitis, eosinophilic 
pneumonitis or inflammatory lung disease, increased risk of 
sunburn, increased risk of infection, and rare mood swings 
in children. In general, methotrexate is mostly well tolerated 
and side effects improve with reducing dosage.
Methotrexate is used to treat leukemia, cancers (including 
breast, head and neck, leukemia, lymphoma, lung, osteosar-
coma, bladder, and trophoblastic neoplasms), autoimmune 
diseases (including rheumatoid arthritis, juvenile dermatomy-
ositis, psoriasis, psoriatic arthritis, lupus, sarcoidosis, Crohn’s 
disease, eczema, and many forms of vasculitis), ectopic 
pregnancy, and for the induction of medical abortions.10,11 
Methotrexate is a widely used agent for ocular inflammation 
because of its ease of administration and long track record. 
It is often regarded as the first-line agent when starting a 
patient with uveitis on IMT.
Methotrexate has been reported to be effective in treating 
ocular inflammation in several uncontrolled retrospective 
case studies. In the retrospective Systemic Immunosuppres-
sion for Eye Disease Cohort Study (SITE), which included 
384 patients, methotrexate was found to be moderately 
effective with an overall success of 66% at 12 months for 
Table 2 Approved orphan drugs by the US Food and Drug Administration to be in systemic diseases and/or organ transplantation 
while not received “orphan drug approval” to be used in uveitis (ii) – mechanism and using
Medication Mechanism of 
action
Dosage/route Potential side effects
Methotrexate Antimetabolites/
inhibits dihydrate folate 
reductase
7.5–25 mg per week given with folic acid, 
p.o., S.C.
Gastrointestinal disturbance, hepatotoxicity, oral 
ulcers, fatigue, alopecia, bone marrow suppression, 
pneumonitis, fetal loss, and infections
Tacrolimus T-cell inhibitor/
calcineurin inhibitor
0.1–0.15 mg/kg/day, p.o. Nephrotoxicity, hypertension, diabetes mellitus, 
electrolyte imbalance, and infections
Infliximab Anti-TNFα 3–5 mg/kg loading at weeks 0, 2, and 6, then 
maintenance 3–10 mg/kg every 4–8 weeks; 
maximal dose 20 mg/kg in children, i.v.
Susceptibility to infections, including reactivation of 
tuberculosis, histoplasmosis, hepatitis B, and fungal 
infection; hypersensitivity reactions; demyelinating 
disease; lupus-like syndrome; malignancy; 
thromboembolic events; congestive heart failure
interferon 
α-2a
Biologic/
antiimmunomodulatory 
effects
3–9 million units once daily to three times 
weekly, S.C.
Injection-site reaction, flu-like syndrome, fatigue, 
depression, neutropenia, elevation of liver 
enzymes, and rarely INF α-2a retinopathy
Rituximab Biologic/anti-CD20 1,000 mg or 375 mg/m2 given twice at 
2-week intervals, i.v.
Susceptibility to infections, infusion reactions, 
gastrointestinal disturbance, cardiovascular events, 
muscle spasm, and headache and multifocal 
leukoencephalopathy
Tocilizumab Cytokine receptor 
antibodies/anti-iL-6 
receptor
initial 4 mg/kg every 4 weeks then increase 
to 8–12 mg/kg every 2–4 weeks, i.v.
Serious infections, hypersensitivity reactions, 
hypercholesterolemia, and gastrointestinal 
perforation
Anakinra Cytokine receptor 
antibodies/anti-iL1 
receptor
100 mg daily, S.C. injection-site reaction, infections, headache, 
gastrointestinal disturbance, and fever
Canakinumab Monoclonal antibody 
against iL-1β
Systemic juvenile idiopathic arthritis: 4 mg/kg 
(max 300 mg) S.C. every 4 weeks; cryopyrin-
associated periodic syndromes, 2–3 mg/kg 
SQ every 8 weeks, i.v., S.C.
Susceptibility to infections, headache, nausea, and 
abdominal pain
Alemtuzumab Monoclonal antibody 
against CD52
30 mg i.v., 3 days per week for 12 weeks, 
i.v.
Cytopenias, infusion reactions, infections, 
gastrointestinal disturbance, and insomnia
Abbreviations: iL, interleukin; iNF, interferon; i.v., intravenously; p.o., oral administration; S.C., subcutaneously; TNF, tumor necrosis factor; SQ, subcutaneous.
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sustained control and 58.4% for corticosteroid-sparing 
control (#10 mg). From the data, it appeared to be more 
successful for the treatment of anterior disease; however, the 
authors caution that this observed effect may be related to the 
severity of the disease. It was found to be safe, with just 16% 
patients discontinuing therapy due to side effects, which were 
all reversible.3 Methotrexate was reported to be one of the 
agents of choice for recurrent anterior uveitis, as it was pref-
erentially concentrated in the aqueous humor.12 Galor et al 
reported 90 patients with inflammatory eye disease, includ-
ing 21 patients with scleritis, 17 patients with intermediate 
uveitis, 43 patients with posterior/panuveitis, and 9 patients 
with other types, who were treated with methotrexate. They 
reported that the median time to treatment success was 
6.5 months. The proportion of patients able to discontinue 
prednisone after 6 months of antimetabolite therapy was 6% 
in methotrexate groups.13
Methotrexate is also safe, effective, and the most com-
monly used immunosuppressive agent in children with 
JIA-associated uveitis and chronic anterior or intermediate 
uveitis. In the literature on methotrexate for anterior uveitis 
associated with the seronegative spondyloarthropathies and 
JIA, methotrexate permitted adequate immunosuppression 
and was steroid sparing while maintaining disease control.14 
In a large series of 465 patients with ocular sarcoidosis, 
including 365 patients treated with methotrexate, most cases 
respond well to IMT. This drug was both efficient and well 
tolerated; as 281 (77%) patients continued on methotrexate 
therapy and only 14 (3.8%) had to discontinue it due to drug 
toxicity.15
Recently, intravitreal methotrexate has shown success in 
eyes with uveitic cystoid macular edema (CME).16,17 For the 
treatment of 15 eyes with uveitic CME, statistically signifi-
cant visual improvement of 4 and 4.5 lines occurred at 3 and 
6 months with no statistically significant difference in vision 
when compared to previous treatment with corticosteroids 
or intravitreal triamcinolone acetonide. Relapse occurred at 
a median of 4 months, but reinjection had similar efficacy.18 
Following intravitreal corticosteroids, methotrexate is the 
most widely used intravitreal immunosuppressive agent. The 
dose administrated is 400 µg/0.1 mL, being effective in dif-
ferent inflammatory ocular disorders as well as in masquerade 
syndromes due to intraocular lymphoma.
Tacrolimus
Tacrolimus is a macrolide antibiotic that was isolated 
from the fermentation broth of Streptomyces tsukubaensis. 
Tacrolimus is capable of inhibiting humoral and cellular 
immunity and alloantigen-driven proliferation across strong 
histocompatibility barriers.19
In 1994, a multicenter open clinical trial in Japan con-
ducted on 16 patients with noninfectious uveitis studied 
the clinical effects of tacrolimus. The study included eight 
patients with Behcet’s disease, five patients with VKH, one 
patient with sympathetic ophthalmia, one patient with retinal 
vasculitis, and one patient with sarcoidosis. Results demon-
strated that tacrolimus was effective in treating noninfectious 
uveitis but emphasized the necessity to closely monitor 
patients for the occurrence of adverse effects.20 Tacrolimus 
also showed efficacy and an excellent cardiovascular risk pro-
file when treating 62 patients with noninfectious uveitis (4.8% 
anterior uveitis, 25.8% intermediate uveitis, 37.1% posterior 
uveitis, and 32.3% panuveitis) for 4 consecutive years.21 
Another publication evaluated the efficacy of tacrolimus as 
monotherapy versus tacrolimus in combination with systemic 
corticosteroid therapies to achieve remission of inflamma-
tion in noninfectious posterior uveitis. This study showed 
that corticosteroid therapy can be reduced and/or withdrawn 
in patients treated with tacrolimus who are able to achieve 
control of posterior segment intraocular inflammation.22
Tacrolimus therapy showed similar efficacy and a more 
favorable safety profile compared to cyclosporine regard-
ing control of posterior segment intraocular inflammation.23 
Furthermore, the use of topical tacrolimus ointment is effec-
tive in controlling refractory inflammatory ocular surface 
disease and can reduce the need for steroid use while reducing 
inflammation recurrence.24
Infliximab
Infliximab, a chimeric monoclonal antibody that binds both 
circulating and membrane-bound TNF-α, has been reported 
to be effective for the treatment of uveitis associated with 
multiple uveitic diseases, such as human leukocyte antigen 
(HLA)-B27-related anterior uveitis, pars planitis, VKH, bird-
shot chorioretinopathy, recalcitrant uveitic CME, multifocal 
choroiditis, sympathetic ophthalmia, serpiginous choroidopa-
thy, and idiopathic uveitis.25–27
In addition, infliximab has been described to be a rapid 
and very effective therapy for the treatment of ABD-related 
panuveitis and retinal vasculitis.28,29 Sfikakis et al reported in 
a prospective study of 25 patients with ABD-related uveitis 
that .90% of patients demonstrated the resolution of vitritis, 
CME, retinitis, and retinal vasculitis within 4 weeks after ini-
tiating infliximab therapy and benefit often occurred in under 
1 week.29 It was shown to be more effective than conventional 
immunotherapy for ABD-related retinal vasculitis.30
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Infliximab also showed efficacy for JIA uveitis, with the 
majority of patients experiencing rapid control of uveitis after 
the second infusion.31,32 However, multiple case reports and 
series suggest that TNF-α inhibitors may cause sarcoidosis-
like conditions. TNF inhibitors analogously are effective for 
psoriasis, but they have also been reported to cause psorias-
iform skin disease and developing drug-induced lupus.33,34 
Furthermore, TNF-α inhibitors should be used with caution 
in patients with serpiginous choroidopathy despite previously 
negative QuantiFERON test.35
interferon
INF-α and INF-β are cytokines that have an important role 
in treating severe sight-threatening uveitis. INF-α, which is 
naturally secreted in response to viral infection, is categorized 
into INF-α 2a (Roferon-A®) and INF-α2b (Intron-A®). INF 
therapy can cause severe adverse effects including sarcoi-
dosis with or without uveitis.36,37 Thus, this therapy is not 
recommended for the treatment of sarcoid-related uveitis.
INF-α 2a and INF-α 2b have been used for the treat-
ment of posterior uveitis.38 INF-α 2a has been studied 
mostly in patients with ABD.39,40 It has also been reported 
to treat sympathetic ophthalmia, VKH, birdshot retinochor-
oidopathy, intermediate uveitis, and idiopathic panuveitis.39,41 
In a prospective study on patients with sight-threatening 
uveitis, subcutaneous daily use of human INF-α 2b showed 
a favorable response in 83% of the patients.38 INF-α 2b 
has been found to be an effective option in the treatment 
of refractory CME secondary to uveitis as well.42 Finally, 
INF-β has been successfully used in treating intermediate 
uveitis associated with multiple sclerosis, choroiditis, and 
choroidal neovascularization in chronic recurrent punctate 
inner choroidopathy.43,44
Rituximab
Rituximab (Rituxan®; Genentech, Inc., South San Francisco, 
CA, USA) is a murine-human chimeric monoclonal antibody 
against CD20 molecule that is expressed on B lymphocytes. 
It is FDA approved for both malignant and nonmalignant 
B-cell-dependent diseases. It has been used in the treatment 
of lymphoma, leukemia, rheumatoid arthritis, granulomatosis 
with polyangiitis, and microscopic polyangiitis.45 Side effects 
of rituximab include infusion reaction, infection especially 
in combination with other immunosuppressive medications, 
and progressive multifocal leukoencephalopathy.
Current information about the use of rituximab in oph-
thalmology is limited. Rituximab has been used success-
fully in the treatment of JIA-associated uveitis, particularly 
in oligoarthritic (rather than polyarthritic) JIA.46,47 
In concurrence, Miserocchi et al observed long-term remis-
sion of uveitis in patients with JIA who were treated with 
rituximab.45 The efficacy of rituximab in refractory ocular 
involvement of systemic lupus erythematosus,48 ABD,49 bird-
shot retinochoroidopathy,50 and type II essential cryoglobu-
linemia refractory to steroid treated with plasmapheresis has 
also been shown, although ABD is known to be a predomi-
nantly T-cell-mediated disease.51
Tocilizumab
Tocilizumab (Actemra®; Genentech, Inc.) is a monoclonal 
antibody against interleukin (IL)-6 receptors. It has been 
approved for the treatment of moderate-to-severe rheumatoid 
arthritis and polyarticular and systemic JIA refractory to other 
biologic response modifiers.
Tocilizumab has been successfully used in refractory 
JIA-associated uveitis, birdshot retinochoroidopathy, ABD, 
and refractory idiopathic uveitis.52–57 Hirano et al described 
a case of severe ABD-associated posterior uveitis resistant 
to conventional immunosuppression and infliximab infu-
sions who experienced complete remission after tocilizumab 
monotherapy.58 Tocilizumab was also used for a case of 
multicentric Castleman disease with the resolution of uveitis 
and perivascular leakage on fluorescein angiography at 
3 months after treatment.59 The efficacy of tocilizumab in 
noninfectious intermediate, posterior, or panuveitis and 
in JIA-associated uveitis is currently being examined in 
two separate ongoing phase I/II clinical trials.60 Adán et al 
demonstrated the effectiveness of tocilizumab in treating 
uveitic CME refractory to conventional chemotherapy.55 
Tocilizumab was also reported to improve visual acuity and 
decrease in macular thickness in optical coherence tomog-
raphy in birdshot retinochoroidopathy, JIA, and idiopathic 
panuveitis-associated CME.56,57
Although tocilizumab therapy is employed to improve 
rheumatologic symptoms, there are two case reports in regard 
to possible paradoxical inflammatory responses in patients 
treated with tocilizumab. The first patient (HLA-B27-positive 
ankylosing spondylitis) developed uveitis for the first time 
after treatment, and the second patient (rheumatoid arthritis) 
developed peripheral ulcerative keratitis for the first time 
11 months after tocilizumab treatment.61
Anakinra
Anakinra (Kineret®; Swedish Orphan Biovitrum AB, 
Stockholm, Sweden) is a short-acting recombinant naturally 
occurring human IL-1 receptor antagonist, which blocks IL-1α 
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and IL-β binding to the IL-1 receptor. In a case series of nine 
adult patients with ABD, three of four patients with recurrent 
uveitis showed a complete resolution of intraocular inflam-
mation. Patient inflammation relapsed in an average period 
of 24 weeks. Side effects were observed in three patients that 
included itchy rash at the site of injection and was controlled 
with topical steroids.62 There are currently three case reports 
demonstrating the efficacy of anakinra in infantile posterior 
uveitis63,64 and one report showing efficacy in a patient having 
childhood uveitis associated with Blau syndrome.65
Canakinumab
Canakinumab (Ilaris®; Novartis Pharmaceuticals Corporation, 
Basel, Switzerland) is a human immunoglobulin G1 anti-
IL-1β monoclonal antibody, which is indicated for systemic 
JIA and cryopyrin-associated periodic syndrome in adults and 
children aged $4 years. Its mode of action is based on the 
neutralization of 1β signaling, resulting in the suppression 
of inflammation in patients with disorders of autoimmune 
origin. Reports from clinical trials suggest that canakinumab 
is well tolerated in most patients, and no serious adverse 
effects have been reported. It is administered subcutaneously 
or intravenously every 4–8 weeks. Its effectiveness was 
demonstrated in a refractory case of Behcet’s syndrome-
associated uveitis with a 150-mg single infusion.
Vitale et al reported a case series of three patients (two of 
three patients had ocular involvement, one anterior uveitis, 
and one panuveitis) with Behcet’s disease refractory to 
steroid and multiple immunosuppressive therapies, who 
responded to 150 mg of subcutaneous canakinumab mono-
therapy every 6 weeks. One patient’s uveitis was controlled 
by canakinumab and the other patient achieved remission on 
anakinra and remained in remission on canakinumab after 
stopping anakinra due to side effects.66 Ugurlu et al described 
a case of a 16-year-old female with severe bilateral panuveitis 
with hypopyon and retinal vasculitis associated with ABD. 
The patient was intolerant to INF therapy and refractory 
to conventional immunosuppressive and several biologic 
agents, including infliximab, adalimumab, and anakinra. The 
inflammation resolved with improved visual acuity, which 
was sustained for at least 8 weeks after a single infusion of 
150 mg canakinumab. However, there were no long-term 
outcomes presented.67 Simonini et al reported on the clinical 
response to canakinumab in a 4-year-old boy with sporadic 
nucleotide-binding oligomerization domain-containing pro-
tein 2-associated pediatric granulomatous arthritis and severe 
resistant panuveitis, macular edema, and retinal detachment. 
In this case, canakinumab was given 2 mg/kg each month, 
which led to rapid control of uveitis for at least 6 months.68
Alemtuzumab
Alemtuzumab (Campath®; Genzyme Corporation, Cambridge, 
MA, USA) is a human monoclonal antibody against CD52 
protein on all types of lymphocytes. Alemtuzumab has not 
received FDA approval, thus it is not commercially avail-
able but is obtainable through a restricted distribution pro-
gram by the manufacturer. Adverse effects of alemtuzumab 
include significant lymphopenia; secondary autoimmunity, 
specifically Graves’ disease; and idiopathic thrombocy-
topenic purpura.69
Isaacs et al described a case of a 36-year-old male who 
presented with severe panuveitis with choroiditis and retinal 
vasculitis resistant to immunosuppressive agents, including 
cyclophosphamide and intravenous immunoglobulin. The 
patient had significant systemic symptoms, presumably from 
chronic corticosteroid therapy. He was given intravenous 
alemtuzumab with brief improvement of ocular inflammation. 
However, the patient subsequently died with myocardial 
infarction.70 Dick et al reported a series of 10 patients with 
various ocular inflammatory diseases treated with intravenous 
alemtuzumab (four patients with retinal vasculitis, one with 
ABD-related uveitis, and one with sympathetic ophthalmia). 
The first five patients had clinical improvement, but the latter 
with sympathetic ophthalmia had stable inflammation without 
deterioration. Half of the patients flared up during follow-up 
period.71 There is a report of four cases of adult patients with 
Behcet’s disease-associated uveitis, who were treated with a 
single course, at the escalating regimen of 4, 10, 40, 40, and 
40 mg intravenously daily, for 5 consecutive days, without 
concomitant immunosuppressive agents. They reported 
complete remission in two cases and partial remission in 
two other cases at 6-month follow-up. However, long-term 
remission was observed in only one patient.72
In conclusion, continuing evidence shows that IMT 
agents and biologics orphan drugs approved by the FDA for 
the treatment of systemic diseases are effective in treating 
refractory and recurrent uveitis. These treatments allow for 
reduction in steroid dose and preservation of visual function. 
However, due to the lack of evidence from large random-
ized controlled clinical trials and rarity and heterogeneity of 
uveitis, the use of these drugs still remains “off-label” for 
noninfectious uveitis. We hope that these restrictions and 
limitations will be further addressed in near future.
Our perspective
Uveitis constitutes a sight-threatening disease that should be 
managed according to the severity. Given our current under-
standing of the immune mechanisms of uveitis, IMT drugs can 
greatly reduce inflammation and minimize the use of topical 
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and systemic steroids. There are a number of IMT options 
available that have improved outcomes of uveitic patients 
when used in specific situations. These IMT orphan drugs serve 
as the foundation to modern corticosteroid-sparing therapy.
Conventional IMT agents are the first steroid-sparing 
options for uveitic patients with refractive active inflammation 
and/or sight-threatening complications. Using IMTs in treating 
autoimmune uveitis follows one of the following scenarios: 
1) as a steroid-sparing agent; 2) when corticosteroids fail to 
control the inflammation: persistent, recurrent, or progressing 
in the same eye or bilaterally; 3) when uveitis is associated 
with autoimmune systemic diseases, IMTs are used to control 
both; and 4) with frequent recurrences and/or the development 
of ocular or steroid-induced nonophthalmic complications.
Previous experience indicates that an alternative and/or 
combined IMT regimen is the best treatment choice in cases of 
worsening inflammation. In these worsening patients, a physi-
cian can either change or add other conventional IMT drugs 
and/or a biologic agent. Medications in the same group can 
be replaced with each other from more aggressive treatments, 
such as infusions to less aggressive ones such as subcutaneous 
injections. Moreover, the failure of a biologic response modi-
fier in a group does not necessarily mean that similar agents 
in the same group will also be ineffective. Corticosteroids are 
usually modulated with IMT drugs according to the degree 
of intraocular inflammation and the possible occurrence of 
complications and/or relapses. In cases of ocular inflammation 
improvement, corticosteroids should be gradually tapered 
until final withdrawal, together with a subsequent reduction 
and/or withdrawal of the use of IMT drugs.
If remission is achieved, there is no consensus on when 
to stop IMT. In our experience, IMT maintenance (without 
corticosteroids) while the patient is in remission should be pro-
longed for a period of 2 years before considering tapering the 
medication, in order to achieve stable control of the disease and 
to reduce the probability of recurrence. The end point of IMT 
is also determined by the presence of the underlying systemic 
autoimmune disease that is being controlled by the same IMT, 
which often requires coordination between the ophthalmolo-
gist and the rheumatologist. Additional controlled trials are 
needed to assess long-term remission outcomes after IMT 
tapering and develop proper end points of IMT regimens.
Lack of randomized controlled clinical trials, rarity and 
heterogeneity of uveitis, and the high cost of these agents 
make using IMTs and biologics challenging in ophthalmology. 
Among the studies referenced in this study, most are small 
retrospective clinical trials, which have no standard treat-
ment regimen, definition of success or remission, and little 
consensus on IMT end points. Nowadays, the number of 
IMT therapeutic options in uveitis has expanded vastly. 
It remains imperative for a clinician to diagnose the disease 
early and institute aggressive therapy. Furthermore, selec-
tion, administration, and monitoring of IMT sometimes need 
coordination with a rheumatologist and/or a chemotherapist 
to avoid complications.
There are many other biologic response modifiers that 
have been employed for the treatment of systemic autoim-
mune diseases and experimental autoimmune uveitis that 
are promising for the treatment of idiopathic noninfectious 
uveitis. The development of monoclonal antibodies that 
recognize two or more targets at the same time, and the 
development of a safe and effective local sustained-release 
device delivering biologic response modifiers may be promis-
ing approaches for treatment in the future.
As our understanding of autoimmune diseases expands, 
new targets and approaches to treatment are becoming 
available. We emphasize the need for the FDA to approve 
“on-label” use of current orphan IMT agents and biolog-
ics more quickly and to facilitate insurance coverage and 
expanded access to uveitis patients. Further assessment of 
current IMT agents and new IMT regimens is needed to pro-
vide evidence confirming the efficacy, optimal dose, regimen, 
maintenance, and end point for the treatment of uveitis.
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